Form 4 for ACRV Acrivon Therapeutics, Inc.
Accepted 2026-08-06 16:34:32 ET · period of report 2026-08-04 · accession 0000905148-26-003499 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-08-06 16:34 | 2026-08-04 | ACRV | Levy Adam D. | CFO | S - Sale | $1.57 | -1,142 | 66.0K | -2% | -$1,793 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-08-04 | S | D | 1,142 | $1.57 | 66,008 | D | — | — | (F1) Shares sold automatically to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units. |